Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 25:85:103319.
doi: 10.1016/j.eclinm.2025.103319. eCollection 2025 Jul.

Effectiveness of recombinant zoster vaccine in reducing herpes zoster incidence and all-cause mortality among patients with rheumatoid arthritis: a retrospective cohort study of 21,046 individuals from TriNetX U.S. Collaborative Network

Ying-Li Lin  1   2   3 , Shiow-Ing Wang  2   4 , James Cheng-Chung Wei  2   5   6   7   8
Affiliations

Effectiveness of recombinant zoster vaccine in reducing herpes zoster incidence and all-cause mortality among patients with rheumatoid arthritis: a retrospective cohort study of 21,046 individuals from TriNetX U.S. Collaborative Network

Ying-Li Lin et al. EClinicalMedicine. .

Abstract

Background: Patients with rheumatoid arthritis (RA) are at increased risk of developing herpes zoster (HZ). This study aimed to assess the effectiveness of recombinant zoster vaccine (RZV) in reducing both the incidence of HZ and all-cause mortality among individuals with RA.

Methods: We conducted a retrospective cohort study using data from the TriNetX U.S. Collaborative Network between October 1, 2017 and March 31, 2024. The study population consisted of patients with RA who received RZV (RA-RZV cohort) and those who did not (RA control cohort). Propensity score matching (PSM) was employed to balance baseline characteristics between the groups, accounting for demographics, social economic status, lifestyles, medical utilization, comorbidities, and medications. The primary outcomes were the risk of HZ and all-cause mortality. PSM-adjusted hazard ratios (HRs) were calculated using Cox proportional hazards regression models. Kaplan-Meier curves and Log-Rank tests were used to evaluate survival differences.

Findings: After PSM, each cohort included 21,046 individuals. The RA-RZV group demonstrated significantly lower risks of HZ (HR: 0.836, 95% CI: 0.738-0.947) and all-cause mortality (HR: 0.606, 95% CI: 0.561-0.654). The HZ risk reduction was more pronounced in patients aged 50-64 years (HR: 0.731, 95% CI: 0.610-0.876), females (HR: 0.791, 95% CI: 0.684-0.915), White (HR: 0.808, 95% CI: 0.696-0.937), and Black/African American participants (HR: 0.685; 95% CI: 0.481-0.976).

Interpretation: RZV vaccination is associated with a reduced risk of HZ among patients with RA aged 50 years and older. While we observed a reduction in all-cause mortality among RZV recipients, this finding should be interpreted with caution, as the effect size may not be entirely attributable to HZ prevention alone. Given the established efficacy of RZV in preventing HZ and its potential to reduce mortality, vaccination should be prioritized among eligible patients with RA.

Funding: There is no funding.

Keywords: Herpes zoster; Mortality; Recombinant zoster vaccine; Rheumatoid arthritis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Selection process.
Fig. 2
Fig. 2
Kaplan–Meier curve of herpes zoster.
Fig. 3
Fig. 3
Kaplan–Meier curve of all-cause mortality.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Di Matteo A., Bathon J.M., Emery P. Rheumatoid arthritis. Lancet. 2023;402(10416):2019–2033. - PubMed
    1. Safiri S., Kolahi A.A., Hoy D., et al. Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis. 2019;78(11):1463–1471. - PubMed
    1. Mehta B., Pedro S., Ozen G., et al. Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study. RMD Open. 2019;5(1) - PMC - PubMed
    1. de Almeida A.L.B., Guimarães M., da Costa Pinto M.R., et al. Predictors of serious infections in rheumatoid arthritis-a prospective Brazilian cohort. Adv Rheumatol. 2024;64(1):23. - PubMed
    1. Asada H. Recent topics in the management of herpes zoster. J Dermatol. 2023;50(3):305–310. - PubMed

LinkOut - more resources